Obesity and androgens: facts and perspectives

Fertility and Sterility

Volumn 85, Issue 5, 2006, Pages 1319-1340

  Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BIOFUEL; CYPROTERONE ACETATE; DROSPIRENONE; ENZYME; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTODENE; GHRELIN; GONADORELIN AGONIST; GONADOTROPIN; LEPTIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE;

ABDOMEN; ADIPOSE TISSUE; ALOPECIA; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROGEN RELEASE; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WEIGHT; DATA ANALYSIS; GONADOTROPIN RELEASE; HIRSUTISM; HOMEOSTASIS; HORMONE ACTION; HORMONE DETERMINATION; HORMONE TRANSPORT; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; INFORMATION RETRIEVAL; LIPID METABOLISM; METABOLIC SYNDROME X; MOLECULAR MECHANICS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PUBLICATION; REGULATORY MECHANISM; REPRODUCTION; SEX DIFFERENCE; STEROIDOGENESIS; THEORY; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

CLINICAL TRIALS; COMORBIDITY; EVIDENCE-BASED MEDICINE; FEMALE; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; OBESITY; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 33646110761     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2005.10.054     Document Type: Article

References (223)

1. Pinkey J.H., and Kopelman P.G. Endocrine determinant of obesity. In: Bray G.A., and Bouchard C. (Eds). Handbook of obesity. Etiology and pathophysiology. 2nd ed. (2004), Marcel Dekker, New York 655-670
2. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest 106 (2000) 473-481
3. Wajchenberg B.L. Subcutaneous and visceral adipose tissue. their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
4. Pasquali R., and Vicennati V. Obesity and hormonal abnormalities. In: Bjorntorp P. (Ed). International textbook of obesity (2001), John Wiley & Sons, Chichester (UK) 225-239
5. Pasquali R., Pelusi C., Genghini S., Cacciari M., and Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 9 (2003) 1-14
6. Hu F.C.W., and von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 24 (2003) 183-217
7. Von Shoultz B., and Carlstrom K. On the regulation of sex-hormone-binding globulin. A challenge of old dogma and outlines of an alternative mechanism. J Steroid Biochem 32 (1989) 327-334
8. Tchernof A., and Despres J.P. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32 (2000) 526-536
9. Pasquali R., Casimirri F., Platé L., and Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm Metab Res 22 (1990) 303-306
10. Evans D.J., Hoffmann R.G., Kalkhoff R.K., and Kissebah A.H. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 57 (1983) 304-310
11. Samojlik E., Kirschner M.A., Silber D., Schneider G., and Ertel N.H. Elevated production and metabolic clearance rates of androgens in morbidly obese women. J Clin Endocrinol Metab 59 (1984) 949-954
12. Kirschner M.A., Samojlik E., Drejka M., Szmal E., Schneider G., and Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70 (1990) 473-479
13. Kurtz B.R., Givens J.R., Komindrr S., Stevens M.D., Karas J.G., Bittle J.B., et al. Maintenance of normal circulating levels of Δ4-androstenedine and dehydroepiandrosterone in simple obesity despite increased metabolic clearance rates. evidence for a servo-control mechanism. J Clin Endocrinol Metab 64 (1987) 1261-1267
14. Smith S.R. The endocrinology of obesity. Endocr Metab Clin North Am 25 (1996) 921-942
15. Zumoff B., Strain G., Miller L.K., Rosner W., Senie R., Seres D., et al. Plasma free and nonsex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71 (1990) 929-931
16. Strain G.W., Zumoff B., Kream J., Strain J.J., Deucher R., Rosenfeld R.S., et al. Mild hypogonadotropic hypogonadism in obese men. Metabolism 31 (1982) 871-875
17. Tchernoff A., Després J.-P., Bélanger A., Dupont A., Prud'homme D., Moorjani S., et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 44 (1995) 513-519
18. Kokkoris P., and Pi-Sunyer F.X. Obesity and endocrine diseases. Endrocrinol Metab Clin North Am 32 (2003) 895-914
19. Vermeulen A., Kaufman J.M., Deslypere J.P., and Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76 (1993) 1140-1146
20. Giagulli Giagulli V.A., Giorgino R., and Vermeulen A. Origin and significance of plasma androsterone glucuronide levels. a parameter of adrenal androgen secretion and hepatic 5 alpha-reductase activity. J Clin Endocrinol Metab 76 (1993) 918-923
21. Khaw K.T., and Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 2 (1992) 675-682
22. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli Labate A.M., Fabbri R., et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 40 (1991) 101-104
23. Leenen R., van der Koy K., Seidell J.C., Deurenberg P., and Kopperschaar H.P.F. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 78 (1994) 1515-1520
24. Plymate S.R., Matej L.A., Jones R.E., and Friedl K.E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67 (1988) 460-464
25. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20 (1999) 535-582
26. Gambineri A., Pelusi C., Vicennati V., Pagotto U., and Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes 26 (2002) 883-896
27. Pasquali R., Casimirri F., De Iasio R., Mesini P., Boschi S., Chierici R., et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80 (1995) 654-658
28. Pitteloud N., Hardin M., Dwyer A.A., Valassi E., Yialamas M., Elahi D., et al. Increasing insulin resistance is associated with a decrease in leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90 (2005) 2636-2641
29. Siiteri P.K., and McDonald P.C. Role of extraglandular estrogen in goman endocrinology. In: Greep P.O., and Astwood E. (Eds). Female reproduction system (1973), American Physiological Society, Washington (DC) 615 Handbook of physiology. Sect. 7: Endocrinology. Vol. 11
30. Schneider J., Bradlow H.L., Strain G., Levin J., Anderson K., and Fishman J. Effect of obesity on estradiol metabolism. decreased formation of nonuterotropic metabolites. J Clin Endocrnol Metab 56 (1983) 973-978
31. Yen S.S.C., Chaney C., and Judd H.L. Functional aberrations of the hypothalamic-pituitary system in polycystic ovary. A consideration of the pathogenesis. In: James W.H.T., Serio M., and Giusti G. (Eds). The endocrine function of the human ovary (1976), Academic Press, New York 373-380
32. McKenna T.J. Pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med 318 (1988) 558-562
33. Longcope C., Kato T., and Horton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest 48 (1969) 2191-2201
34. Glass A.R. Endocrine aspects of obesity. Endocr Metab Clin North Am 73 (1989) 139-160
35. Pasquali R., Casimirri F., Melchionda N., Fabbri R., Capelli M., Platé L., et al. Weight loss and sex steroid metabolism in massively obese men. J Endocrinol Invest 11 (1988) 205-210
36. Strain G.W., Zumoff B., Miller L.K., et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab 66 (1988) 1019-1023
37. Blank D.M., Clark R.V., Heymsfield S.B., Rudman D.R., and Blank M.S. Endogenous opioids and hypogonadism in human obesity. Brain Res Bull 34 (1994) 571-574
38. Stanik S., Dornfeld L.P., Maxwell M.H., Viosca S.P., and Korenman S.G. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab 53 (1981) 828-832
39. Zumoff B., Miller L.K., and Strain G.W. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52 (1999) 1126-1128
40. Williams T., Berelowitz M., Joffe S.N., Thorner M.O., Rivier J., Vale W., et al. Impaired growth hormone response to growth hormone releasing factor in obesity. a pituitary defect reversed with weight reduction. N Engl J Med 311 (1984) 1403-1407
41. Couse J.F., and Korach K.H. Estrogen receptor null mice. what have we learned and where they lead us?. Endocr Rev 20 (1999) 358-417
42. Smith E.P., Boyd J., Frank G.R., Takasashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331 (1994) 1056-1061
43. Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337 (1997) 91-95
44. The Writing Group for the PEPI Trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopaual women. JAMA 273 (1996) 199-208
45. Jensen L.B., Vestergaard P., Hermann A.P., Gram J., Eiken P., Abrahamsen B., et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women. a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 18 (2003) 333-342
46. Murata Y., Robertson K.M., Jones M.E.E., and Simpson E.R. Effect of estrogen deficiency in the male. the ArKO mouse model. Mol Cell Endocrinology 193 (2002) 7-12
47. Jones M.E.E., Thorburn A.W., Britt K.L., Hewitt K.N., Wreford N.G., Proietto J., et al. Aromatase deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 97 (2000) 12735-12740
48. Taylor J.A., Lewis K.J., and Lubahn D.B. Estrogen receptor mutations. Mol Cell Endocrinol 145 (1998) 61-66
49. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 20 (1996) 291-302
50. Pasquali R., and Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary-adrenal axis in humans. Horm Metab Res 32 (2000) 521-525
51. Bjorntorp P. Centralization of body fat. In: Bjorntorp P. (Ed). International textbook of obesity (2001), John Wiley & Sons, Chichester (UK) 213-224
52. Rebuffé-Scrive M., Lundholm K., and Bjorntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest 15 (1985) 267-271
53. Sandeep T.C., and Walker B.R. Pathophysiology of modulation of local glucocorticoid levels by11 β -hydroxysteroid dehydrogenase. Trends Endocrinol Metab 12 (2001) 446-453
54. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11β-hydroxysteroid dehydrogenase type 1. a tissue specific regulation of glucorticoid response. Endocr Rev 25 (2004) 831-866
55. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
56. Tilbrook A.J., Turner A.I., and Clarke I.J. Effects of stress on reproduction in nonrodent mammals. the role of glucocorticoids and sex differences. Rev Reprod 5 (2000) 105-113
57. Handa R.J., Burgess L.H., Kerr J.E., and O'Keefe J.A. Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. Horm Behav 28 (1994) 464-476
58. Viau V., and Meaney M.J. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J Neurosci 16 (1996) 1866-1876
59. Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J Neuroendocrinol 14 (2002) 506-513
60. Born J., Ditschuneit I., Schreiber M., Dodt C., and Fehm H.L. Effects of age and gender on pituitary-adrenocortical responsiveness in humans. Eur J Endocrinol 132 (1995) 705-711
61. Vierhapper H., Nowotny P., and Waldhausl W. Production rates of testosterone in patients with Cushing's syndrome. Metabolism 49 (2000) 229-231
62. Lado-Abeal J., Rodriguez-Arnao J., Newell-Price J.D., Perry L.A., Grossman A.B., Besser G.M., et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83 (1998) 3083-3088
63. Vicennati V., Ceroni L., Genghini S., Patton L., Pagotto U., and Pasquali R. Sex difference in the relationship between the hypothalamic-pituitary-adrenal (HPA) axis and sex hormones in obesity. Obes Res 14 (2006)
64. Moschos S., Chan J.L., and Mantzoros C.S. Leptin and reproduction. a review. Fertil Steril 77 (2002) 433-444
65. Mantzoros C.S., and Moschos S. Leptin. in search for role(s) in human physiology and pathophysiology. Clin Endocrinol (Oxf) 49 (1998) 551-567
66. Fasshauer M., and Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46 (2003) 1594-1603
67. Licinio J., Negrao A.B., Mantzoros C., Kaklamani V., Wong M.L., Bongiorno P.B., et al. Sex difference in circulating leptin pulse amplitude. clinical implications. J Clin Endocrinol Metab 83 (1998) 4140-4147
68. Montague C.T., Prins J.B., Sanders l., Digby J.E., and O'Rahilly S. Depot- and sex specific differences in human leptin mRNA expression. implications for the control of regional fat distribution. Diabetes 46 (1997) 342-347
69. Shimizu H., Shimomura K., Negishi M., Masumago M., Uehara Y., Sato N., et al. Circulating concentrations of soluble leptin receptor. influence of menstrual cycle and diet. Nutrition 18 (2002) 309-312
70. McConway M.G., Johnson D., Kelly A., Griffin D., Smith J., and Wallace A.M. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 37 (2000) 717-723
71. Housecknecht K.L., Mantzoros C.S., Kuliawat R., Hadro E., Flier J.S., and Kahn B.B. Evidence for leptin binding to proteins in serum of rodents and humans. modulation with obesity. Diabetes 45 (1996) 1638-1643
72. Jin L., Zhang S., Burguera B.G., Couce M.E., Osamura R.Y., Kulig E., et al. Leptin and leptin receptor expression in rat and mouse pituitary cells. Endocrinology 141 (2000) 333-339
73. Machinal F., Dieudonne M.N., Leneveu M.C., Pecquery R., and Guidicelli Y. In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes. evidence for a regional specific regulation by sex steroid hormones. Endocrinology 140 (1999) 1567-1574
74. Tartaglia L.A. The leptin receptor. J Biol Chem 272 (1997) 6093-6096
75. Terasawa F. Cellular mechanism of pulsatile LHRH release. Gen Com Endocrinol 112 (1998) 283-295
76. Yu W.H., Kimura M., Walczewska A., Kaant S., and McCann S.M. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A 94 (1997) 1023-1028
77. Spicer J.L., and Francisco C.C. The adipose obese gene product, leptin. evidence of a direct inhibitory role in ovarian function. Endocrinology 138 (1997) 3374-3379
78. Caprio M., Isidori A.M., Carta A.R., Moretti C., Dufau M.L., and Fabbri A. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 140 (1999) 4939-4947
79. Barash I.A., Cheung C.C., Weigle Ds., Ren H., Kabigting E.B., Kuijper J.I., et al. Leptin is a metabolic signal to the reproduction system. Endocrinology 137 (1996) 3144-3147
80. Chehab F.F., Lim M.E., and Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12 (1996) 318-320
81. Faroqui L.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 (2002) 1093-1103
82. Clement K., Vaisse C., Lahlou N., Cabrol S., Pelloux V., Cassuto D., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 (1998) 398-401
83. Oral E.A., Ruiz E., Andewelt A., Sebring N., Wagner A.J., Depaoli A.M., et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 87 (2002) 3110-3117
84. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
85. Sahu A. Minireviw. a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 145 (2004) 2613-2620
86. Vettor R., De Pergola G., Pagano C., Englaro P., Laudadio E., Giorgino F., et al. Gender differences in serum leptin in obese people. relationship with testosterone, body fat distribution and insulin sensitivity. Eur J Clin Invest 27 (1997) 1016-1024
87. Jockenhovel F., Blum W.F., Vogel E., Englaro P., Muller-Wieland D., Reinwein D., et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 82 (1997) 2510-2513
88. Wabitsch M., Blum W.S., Muche R., Braun M., Hube F., Rascher W., et al. Contribution of androgens to the gender differences in leptin production in obese children and adolescents. J Clin Invest 100 (1997) 808-813
89. Rosembaum M., Nicolson M., Hirsch J., Haymsfield S.B., Gallagher D., Chu F., et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 81 (1996) 34247
90. Isidori A.M., Caprio M., Strollo F., Moretti C., Frajese G., Isidori A., et al. Leptin and androgens in male obesity. evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84 (1999) 3673-3680
91. Agarwal S.K., Vogel k., Weistman S.R., and Magoffin D.A. Leptin antagonizes the insulin-like factor-1 augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab 84 (1999) 1072-1076
92. Spicer J.L., and Francisco C.C. Adipose obese gene product, leptin, inhibits bovine ovarian thecal cell steroidogenesis. Biol Reprod 58 (1998) 207-212
93. Duggal P.S., Van Der Hoek K.H., Milner C.R., Ryan N.K., Armstrong D.T., Magoffin D.A., et al. The in vivo and in vitro effects of exogenous leptin on ovulation in the rat. Endocrinology 141 (2000) 1971-1976
94. Zachow R.J., and Magoffin D.A. Direct intraovarian effects of leptin. impairment of the synergistic action of insulin-like growth factor-I on FSH-dependent 17β-estradiol production by rat ovarian granulosa cells. Endocrinology 1378 (1997) 847-850
95. Urbancsek J., Fedorcsak P., Klinga K., Devènyi N., Papp Z., Rabe T., et al. Impact of obesity and leptin levels on the secretion of estradiol inhibin A and inhibin B during ovarian stimulation with gonadotropins. Gynecol Endocrinol 16 (2004) 285-292
96. Geisthovel F., Meysing A., and Brabant G. C-peptide and insulin, but not c19 steroids, support the predictive value of body mass index on leptin in serum of premenopausal women. Hum Reprod 13 (1998) 547-553
97. Saad M.F., Damani S., Gingerich R.L., Riad-Gabriel M.G., Khan A., Boyadjian R., et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 82 (1997) 579-584
98. Brzechffa P.R., Jakimiuk A.J., Agarwal S.A., Weitsman S.R., Buyalos R.P., and Magoffin D.A. Serum immunoreactive leptin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 81 (1996) 4166-4169
99. Vicennati V., Gambineri A., Calzoni L., Casimirri F., Macor C., Vettor R., et al. Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47 (1998) 988-992
100. Veldhuis J.D., Pincus S.M., Garcia-Rudaz M.C., Ropelato M.G., Escobar M.E., and Barontini M. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 3772-3778
101. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., et al. A receptor in pituitary and hypothalamus that function in growth hormone release. Science 273 (1996) 974-977
102. Arvat E., Di Vito L., Broglio F., Papotti M., Muccioli G., Dieguez C., et al. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 23 (2000) 493-495
103. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 402 (1999) 656-660
104. Casanueva F., and Dieguez G. Ghrelin. the link connecting growth with metabolism and energy homeostasis. Rev Endocr Metab Dis 3 (2002) 325-338
105. Tschop M., Weyer C., Tataranni A.P., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
106. Shiiya T., Nakazato M., Minuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
107. Yildiz B.O., Suckard M.A., Wong Ml., McCann S.M., and Licinio J. Alterations of the dynamics of circulating ghrelin, adiponectin, and leptin in humans. Proc Natl Acad Sci U S A 101 (2004) 10434-10439
108. Cummings D.E., DE, Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., and Dellinger J.Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
109. Ukkola O., Ravussin E., Jacobson P., Perisse l., Rankinen T., Tschop M., et al. Role of ghrelin polymorphism in obesity based on three different studies. Obes Res 10 (2002) 782-791
110. Goldstone A.P. Prader-Willy syndrome. advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 15 (2004) 12-20
111. Korbonits M., Goldstone A.P., Guerguiev M., and Grossman A.B. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol 25 (2004) 27-68
112. Barkan A.L., Dimaraki E.V., Jessup S.K., Symons K.V., Ermolenko M., and Jaffe C.A. Ghrelin secretion in humans is sexually dymorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88 (2003) 2180-2184
113. van der Lely A.J., Thchop M., Heiman M.L., and Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25 (2004) 426-457
114. Papotti M., Ghe C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., and Muccioli G. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85 (2000) 3803-3807
115. Gnanapavan S., Kola B., Bustin S.A., Morris D.G., McGee P., Fairclough, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87 (2002) 2988-2991
116. Tena-Sempere M., Barreiro M.L., Gonzalez L.C., Gaytan F., Zhang F.P., Caminos J.E., et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology 143 (2002) 717-725
117. Barreiro M.L., Gaytán F., Caminos J.E., Pinilla L., Casanueva F.F., Aguilar E., et al. Cellular location and hormonal regulation of ghrelin expression in rat testis. Biol Reprod 67 (2002) 1768-1776
118. Barreiro M.L., Suominen J.S., Gaytan F., Pinilla L., Chopin L.K., Casanueva F.F., et al. Developmental, stage-specific and hormonally regulated expression of growth hormone secretagogue receptor messenger ribonucleic acid in rat testis. Biol Reprod 68 (2003) 1631-1640
119. Tanaka M., Hayashida Y., Nakao N., Nakai N., and Nakashima K. Testis-specific and developmentally induced expression of a ghrelin gene-derived transcript that encodes a novel polypeptide in the mouse. Biochem Biophys Acta 1522 (2001) 62-65
120. Papotti M., Ghe C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85 (2000) 3803-3807
121. Pagotto U., Gambineri A., Pelusi C., Genghini S., Cacciari M., Otto B., et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab 88 (2003) 4139-4143
122. Gambineri A., Pagotto U., De Iasio R., Meriggiola M.C., Costantino A., Patton L., et al. Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal men. J Endocrinol Invest 28 (2005) 241-246
123. Caminos J.E., Tena-Sempere M., Gaytan F., Sanchez-Criado J.E., Barreiro M.L., Nogueiras R., et al. Expression of ghrelin in the cyclic and pregnant ovary. Endocrinology 144 (2003) 1594-1602
124. Gaytán F., Barreiro M.L., Chopin L.K., Herington A.C., Morales C., Pinilla L., et al. Immunolocalization of ghrelin and its functional receptor, the type 1a GH-secretagogue receptor, in the cyclic human ovary. J Clin Endocrinol Metab 88 (2003) 879-887
125. Barkan A.L., Dimaraki E.V., Jessup S.K., Symons K.V., Ermolenko M., Jaffe C.A., et al. Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88 (2003) 2180-2184
126. Ariyasu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86 (2001) 4753-48
127. Pagotto U., Gambineri A., Vicennati V., Heiman M.L., Tschöp M., and Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome. correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 87 (2002) 5625-5629
128. Schöfl C., Horn R., Schill T., Schlösser H.W., Müller M.J., and Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 4607-4610
129. Gambineri A., Pagotto U., Tschöp M., Vicennati V., Manicardi E., Carcello A., et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 26 (2003) 493-498
130. Moran L.J., Noakes M., Clifton P.M., Wittert G.A., Tomlinson L., Galletly C., et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 89 (2004) 3337-3344
131. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22 (1994) 3181-3186
132. Kazemi-Esfariani P., trifiro M.A., and Pinski L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor. possible pathogenetic relevance for the (CAG)n-expanded neuropathies. Hum Mol Genet 4 (1995) 523-527
133. Westberg I., Baghaei F., Rosmond R., Hellstrand M., Landen M., Jansson M., et al. Polymorphisms of the androgen receptor gene and the estrogen beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 86 (2001) 2562-2568
134. Irvine R.A., Ma H., Yu M.C., Ross R.K., Stallcup M.R., and Coetzee G.A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamide length. Hum Mol Genet 9 (2000) 267-274
135. Sato T., Matsumoto T., Yamada T., Watanabe T., Kawano H., and Kato S. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Comm 300 (2003) 167-171
136. Krithivas K., Yurgalevitch S.M., Mohr B.A., Wilcox C.J., Batter S.J., Brown M., et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 162 (1999) 137-142
137. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., et al. The CAG repeat within the androgen receptor gene and its relationship with prostate cancer. Proc Natl Acad Sci U S A 94 (1997) 3320-3323
138. Giovannucci E., Platz E.A., Stampfer M.J., Giovannucci E., Platz E.A., Stampfer M.J., et al. The CAG repeat within the androgen receptor gene and benign proastate hyperplasia. Urology 53 (1999) 121-125
139. Dowsing A.T., Young E.L., Clarck M., McLachlan R.I., de Kretser D.M., and Trounson A.O. Linkage between male infertility and tronucleotide repeat expansion in the androgen-receptor gene. Lancet 354 (1999) 640-643
140. Gustafson D.R., Wen M.J., and Koppanati B.M. Androgen receptor gene repeats and indices of obesity in older adults. Int J Obes 27 (2003) 75-81
141. Mifsud A., Ramirez S., and Yong E.L. Androgen receptor gene CAG trinucleotide repeats in anovulatoty infertility and polycystic ovaries. J Clin Endocrinol Metab 83 (2000) 3484-3488
142. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 161-165
143. Legro R.S., Shabahrami B., Lobo R.A., and Kovacs B.W. Size polymorphism of the androgen receptor among female hispanics and correlation with androgenic characteristics. Obstet Gynecol 83 (1994) 701-706
144. Ibanez L., Ong K.K., Mongan N., Jaaskelainen J., Marcos M.V., Hughes I.A., et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 88 (2003) 3333-3338
145. Joyner J., Hutley L., and Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. Horm Metab Res 34 (2002) 223-228
146. Stewart P.M., Shackleton C.H., Beastall G.H., and Edwards C.R. 5a-reductase activity in polycystic ovary syndrome. Lancet 335 (1990) 431-433
147. Fassnacht M., Schlenz N., Schneider S.B., Wudy S.A., Allolio B., and Arlt W. Behind adrenal and ovarian androgen generation. increased peripheral 5a-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2760-2766
148. Adamski J., and Jacob F.J. A guide to 17 β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 171 (2001) 1-4
149. Luu-The V. Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 76 (2001) 143-151
150. Corbould A.M., Badwen M.J., Lavranos T.C., Rogers R.J., and Judd D.J. The effect of obesity and the ratio of type 3 17β-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue in women. Int J Obes 26 (2002) 165-175
151. Dufort I., Rheault P., Huang X.-F., Soucy P., and Luu-The V. Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140 (1999) 568-574
152. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., et al. Human 3a-hydroxysteroid dehydrogenases isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily. functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351 (2003) 67-77
153. Blouin K., Richard C., Belanger C., Dupont P., Daris M., Laberge P., et al. Local androgen inactivation in abdominally visceral adipose tissue. J Clin Endocrinol Metab 88 (2003) 5944-5950
154. Quinkler M., Sinha B., Tomlinson J.W., Bujalska I.J., Stewart P.M., and Artl W. Androgen generation in adipose tissue in women with simple obesity-a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J Endocrinol 183 (2004) 331-342
155. Singh R., Artaza J.N., Taylor W.E., Gonzales-Cadavid N.F., and Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144 (2003) 5081-5088
156. Dieudonne M.N., Pecquery R., Boumedienne A., Leneveu M.C., and Guidicelly Y. Androgen receptors in human preadipocytes and adipocytes. regional specificities and regulation by sex steroids. Am J Physiol 274 (1998) C1645-C1652
157. Pasquali R., Vicennati V., and Pagotto U. Endocrine determinants of fat distribution. In: Bray G., and Bouchard C. (Eds). Handbook of obesity (2003), Marcel Dekker, New York 671-692
158. Cryer A. Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. J Biochem 13 (1981) 525-541
159. Ailhaud G. L'adipocyte, cellule sécrétrice et endocrine. Méd/Sci 14 (1998) 858-864
160. Kern P.A. High adipose tissue lipoprotein lipase activity plays a causal role in the etiology of obesity. In: Angel A., Anderson H., Bouchard C., Lau D., Leiter L., and Mendelson R. (Eds). Progress in obesity research. Proceedings of the 7th International Congress on Obesity; 1994; Toronto, Canada (1994), John Libbey, London 89-94
161. Mayes J.S., and Watson Gh. Direct effect of sex steroid hormones on adipose tissue and obesity. Obes Rev 5 (2004) 197-216
162. Lonnqvist F., Thorne A., Large V., and Arner P. Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler Thromb Vasc Biol 17 (1997) 1472-1480
163. Bonadonna R., and Bonora E. Glucose and free fatty acid metabolism in human obesity. Relationships to insulin resistance. Diabetes Rev 5 (1997) 21-51
164. Lafontan M., and Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34 (1993) 1057-1091
165. Reynisdottir S., Dauzats M., Thorne A., and Langin D. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J Clin Endocrinol Metab 82 (1997) 4162-4166
166. Miller L.K., Kral J.G., Strain G.W., and Zumoff B. Androgen binding to ammonium sulfate precipitates of human adipose tissue cytosols. Steroids 55 (1990) 410-415
167. De Pergola G., Xu X.F., Yang S.M., Giorgino R., and Bjorntorp P. Up-regulation of androgen receptor binding in male rat fat pad adipose precursor cells exposed to testosterone. study in a whole cell assay system. J Steroid Biochem Mol Biol 37 (1990) 553-558
168. Dicker A., Ryden M., Naslund E., Muchlen I.E., Wiren M., Lafontan M., et al. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia 47 (2004) 420-428
169. Marin P., Oden B., and Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men. effects of androgens. J Clin Endocrinol Metab 80 (1995) 239-243
170. Elbers J.M.H., Asscheman H., Seidel J.C., Megens J.A., and Gooren L.J.G. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 79 (1997) 265-271
171. Haarbo J., Marslew U., Gottfredsen A., and Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 40 (1991) 323-326
172. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
173. Hergenc G., Schulte H., Assmann G., and von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 145 (1999) 147-156
174. Tsai E.C., Boyko E.J., Leonetti D.L., and Fujimto W.Y. Low serum testosterone levels as a predictor of increased visceral fat in Japanese-American men. Int J Obes 24 (1996) 485-491
175. Simon D., Charles M.A., Nahoul K., Orssaud G., Kremski J., Hully V., et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men. the TELECOM study. J Clin Endocrinol Metab 82 (1997) 682-685
176. Malkin C.J., Pugh P.J., Jones T.H., and Channer K.S. Testosterone for secondary prevention in men with ischaemic heart disease. Quat J Med 96 (2003) 521-529
177. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., et al., Testosterone gel study group. Trasdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85 (2000) 2839-2853
178. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes 16 (1992) 991-997
179. Buchter D., Behere H.M., Kliesch S., Chirazi A., Nieschlag E., Assmann G., et al. Effect of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp Clin Endocr Diabetes 107 (1999) 522-529
180. Lindstedt G., Lundberg P., Lapidus L., Lundgren H., Bengtsson C., and Bjorntorp P. Low sex hormone binding globulin concentration as an independent risk factor for development of NIDDM. 12 yr follow-up of population study of women in Gotemburg. Diabetes 40 (1991) 123-128
181. Pasquali R., and Gambineri A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online 8 (2004) 431-439
182. De Leo V., la Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-667
183. Gambineri A., Pelusi C., Genghini S., Morselli-Labate A.M., Cacciari M., Pagotto U., et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60 (2004) 241-249
184. Holmang A., Larsson B.M., Brzezinska Z., and Bjorntorp P. The effects of short term testosterone exposure on insulin sensitivity in female rats. Am J Physiol 262 (1992) E851-E855
185. Nilsson C., Niklasson M., Erikson E., Bjorntorp P., and Holmag A. Imprinting of females offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. J Clin Invest 101 (1998) 74-78
186. Dunaif A. Insulin resistance and the polycystic ovary syndrome. mechanisms and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
187. Legro R.S. Diabetes prevalence and risk factors in polycystic ovary syndrome. Curr Opin Endocrinol Diab 9 (2002) 451-458
188. Gambineri A., Pelusi C., Manicardi E., Vicennati V., Cacciari M., Morselli-Labate A.M., et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Phenotype and associated factors. Diabetes 53 (2004) 2353-2358
189. Legro R.S. Polycystic ovary syndrome and cardiovascular disease. a premature association?. Endocr Rev 24 (2003) 302-312
190. Pasquali R., Vicennati V., Scopinaro N., Marinari G., Flamia R., Casimirri F., et al. Achievement of near-normal body weight as the prerequisite to normalize sex hormone-binding globulin concentrations in massively obese men. Int J Obes 21 (1997) 1-5
191. Grenman S., Konnemaa T., Iryale K., Kaiola H.L., and Grouroos M. Sex steroid, gonadotropin, cortisol, and prolactin in healthy, massively obese women. correlation with abdominal fat cell size and effect of weight loss. J Clin Endocrinol Metab 63 (1986) 1257-1261
192. Jakubowicz D.J., and Nestler J.E. 17a-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 82 (1997) 556-560
193. Pasquali R., Gambineri A., Biscotti D., Vicennati V., Gagliardi L., Colitta D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85 (2000) 2767-2774
194. Pasquali R., Casimirri F., Colella P., and Melchionda N. Body fat distribution and weight loss in obese women. Am J Clin Nutr 49 (1989) 185-186
195. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome. systematic review and meta-analysis. BMJ 25 327 (2003) 951-953
196. Bachamann G.A., Bancroft G., Braunstein G., Burger S.R., Davis l., Dennerstein I., et al. Female androgen insufficiency. the Princeton consensus statement on definition, classification and assessment. Fertil Steril 77 (2002) 660-665
197. Davison S.L., and Davis S.R. Androgens in women. J Steroid Biochem Mol Biol 85 (2003) 363-366
198. Lovejoy J.C., Bray G.A., Bourgeois M.O., Macchiavelli R., Rood J.C., Greeson C., et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 81 (1996) 2198-2203
199. Davis S.R., Walker K.Z., and Strauss B.J. Effect of estradiol with or without testosterone on body composition and relationship with lipids in postmenopausal women. Menopause 7 (2000) 395-401
200. Shifren J.L., Braunstein J., Simon P., Casson J.E., Buster R.E., Red Burki E.S., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343 (2000) 682-688
201. Marin P. Effects of androgens in men with the metabolic syndrome. Aging Male 1 (1998) 129-136
202. Li M., and Bjorntorp P. Effects of testosterone and triglycerides uptake and mobilization in different adipose tissues in male rats in vivo. Obes Res 3 (1995) 113-119
203. Woodhouse L.J., Gupta N., Bhasin M., Singh A.B., Ross R., Phillips J., and Bhasin S. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 89 (2004) 718-726
204. Marin P., Holmang S., Gustafsson C., Jonsson L., Sjostrom L., Kvist H., et al. Androgen treatment in abdominally obese men. Obes Res 1 (1993) 245-251
205. Alexandersen P., and Christensen C. The ageing male: testosterone deficiency and testosterone replacement. An up-date. Atherosclerosis 173 (2004) 157-169
206. Svartberg J., von Muhlen D., Schirmer H., Barret-Connor E., Sundfjord J., and Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol 150 (2004) 65-71
207. Boyanow M.A., Boneva Z., and Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6 (2003) 1-7
208. Rittmaster R.S. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28 (1999) 409-421
209. Miller J.A., and Jabobs H.S. Treatment of hirsutism and acne with cyproterone acetate. Clin Endocrinol Metab 15 (1986) 373-389
210. Wynn V., Godsland I.F., Seed M., and Jacobs H.S. Paradoxical effects of the antiandrogen cyproterone acetate on lipid and lipoprotein metabolism. Clin Endocrinol (Oxf) 24 (1986) 183-191
211. De Leo V., La Marca A., Lanzetta D., Cariello P.L., D'Antona D., and Morgante G. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF). Clin Endocrinol (Oxf) 49 (1998) 85-89
212. DiamantiKandarakis E., Mitrakou A., Hennes M.M.I., Platanissiotis D., Kaklas N., Spina J., et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44 (1995) 525-531
213. Ibánez L., Potau N., Marcos M.V., and De Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls. effect of flutamide. J Clin Endocrinol Metab 85 (2000) 3251-3255
214. Eagleson C.A., Gingrich M.B., Pastor C.L., Azora T.K., Bust C.M., Evans W.S., et al. Polycystic ovarian syndrome. evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 85 (2000) 4047-4052
215. De Leo V., Lanzetta D., D'Antona D., La Marca A., and Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 99-102
216. DiamantiKandarakis E., Mitrakou A., Raptis S., Tolis G., and Duleba A.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2699-2705
217. Brogden R.N., and Clissold S.P. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 38 (1989) 185-203
218. Ayub M., and Levell M.J. Inhibition of rat testicular 17a-hydroxylase and 17,20-lyase activities by antiandrogens (flutamide, hydroxyflutamide, RU 23908, cyproterone acetate) in vitro. J Steroid Biochem 28 (1987) 43-50
219. Ibanez L., Ong K., Amin R., Dunger D., and de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 88 (2003) 2600-2606
220. Ibanez L., and de Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism. effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88 (2003) 4720-4724
221. Ibanez L., and de Zegher F. Ethynilestradiol-drospirenoine, fltamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism. opposite effects on adipokines and body adiposity. J Clin Endocrinol Metab (2004) 1592-1594
222. Krattenmaker R. Drospirenone. pharmacology and pharmacokinetics of unique progestagen. Contraception 62 (2000) 29-38
223. Dumesic D.A., Abbott D.H., Eisner J.R., Herrmann R.R., Reed J.E., Welch T.J., et al. Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women. Fertil Steril 70 (1998) 94-101